Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B.
Jang H, Yoon JS, Park SY, Lee HA, Jang MJ, Kim SU, Sinn DH, Seo YS, Kim HY, Kim SE, Jun DW, Yoon EL, Sohn JH, Ahn SB, Shim JJ, Jeong SW, Cho YK, Kim HS, Nam JY, Lee YB, Kim YJ, Yoon JH, Zoulim F, Lampertico P, Dalekos GN, Idilman R, Sypsa V, Berg T, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Janssen H, Papatheodoridis GV, Lee JH.
Jang H, et al.
Clin Gastroenterol Hepatol. 2022 Jun;20(6):1343-1353.e16. doi: 10.1016/j.cgh.2021.09.001. Epub 2021 Sep 6.
Clin Gastroenterol Hepatol. 2022.
PMID: 34500103
We investigated the impact of HBeAg status at the onset of antiviral treatment on the risk of HCC. ...In the Caucasian cohort (n = 719; mean age, 51.8 years; HBeAg-positive, 20.3%; cirrhosis, 34.8%), HBeAg-positivity was not associated with the risk of HCC ei …
We investigated the impact of HBeAg status at the onset of antiviral treatment on the risk of HCC. ...In the Caucasian cohort (n = 71 …